Pancreatic acinar cell carcinoma
MONDO:0006346An adenocarcinoma arising from the pancreas. It is characterized by the presence of relatively uniform malignant cells which form acinar patterns. It usually occurs during adulthood. Signs and symptoms include abdominal pain, weight loss, nausea, and diarrhea. It may metastasize to regional lymph nodes and the liver. A minority of patients develop lipase hypersecretion syndrome. This syndrome may be seen in patients with liver metastases and it is characterized by excessive secretion of lipase in the serum, polyarthralgia, and subcutaneous fat necrosis.
Also known as: Pancreatic acinar cell cancer, acinar cell adenocarcinoma of pancreas, acinar cell adenocarcinoma of the pancreas, acinar cell carcinoma of pancreas, acinar cell carcinoma of the pancreas, carcinoma of pancreatic acinar cell, pancreas acinar cell adenocarcinoma, pancreatic acinar cell adenocarcinoma
2895 clinical trials for this condition and its sub-types, 12 tagged with Pancreatic acinar cell carcinoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Pancreatic acinar cell carcinoma
-
New hope for pancreatic cancer: targeted drug may delay return in BRCA patients
Disease control Recruiting nowThis phase II trial is testing whether the drug olaparib can help prevent pancreatic cancer from coming back in people who have already had surgery and chemotherapy and carry a BRCA1, BRCA2, or PALB2 mutation. Olaparib is a targeted therapy that blocks a repair enzyme cancer cell…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 21, 2026 23:00 UTC
-
Can a genetic test choose the right chemo for pancreatic cancer?
Disease control Recruiting nowThis phase III trial tests whether a genetic signature can guide chemotherapy choice after surgery for pancreatic cancer. Patients are randomly assigned to receive either oxaliplatin-based or gemcitabine-based chemotherapy, chosen either by standard clinical criteria or by a tran…
Phase 3 • Sponsor: John Neoptolemos • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
Triple attack on pancreatic cancer: radiotherapy, chemo, and immunotherapy aim to make tumors removable
Disease control Recruiting nowThis trial tests whether a short course of focused radiation followed by chemotherapy (nab-paclitaxel and gemcitabine) plus the immunotherapy drug camrelizumab can shrink borderline or locally advanced pancreatic tumors enough to allow complete surgical removal. The study enrolls…
Phase 2 • Sponsor: Hebei Medical University Fourth Hospital • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Experimental combo aims to overcome drug resistance in metastatic cancers
Disease control Recruiting nowThis early-stage trial is testing a combination of two chemotherapy drugs (melphalan and BCNU) plus vitamins B12b and C, followed by an infusion of the patient's own stem cells. The goal is to see if this approach is safe for people with metastatic pancreatic or breast cancer, es…
Phase 1 • Sponsor: General Oncology, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC